The NeoCaCRT trial found that SCRT followed by cadonilimab and mFOLFOX6 elicited a pCR of 37.0%, meeting its primary end point for patients with locally advanced rectal cancer.
Join us to watch leading MDS experts present summaries on the most significant abstracts from ASH 2024 followed by interactive panel discussions debating current clinical…
BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
The fourteenth annual edition of the official magazine of the International Brain Tumour Alliance (IBTA).
Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, comments on the long-term safety and efficacy of treosulfan-based conditioning regimens for allogeneic stem cell…
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.
The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.
Frontline belzutifan plus cabozantinib elicited durable responses and was tolerable in patients with treatment-naive advanced ccRCC.
